ALGS (STOCKS)
Aligos Therapeutics, Inc. Common Stock
$8.640000
+0.610000 (+7.60%)
Prev close: $8.030000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lawrence M. Blatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $53.96M
- Employees
- 70
- P/E (TTM)
- -0.93
- P/B (TTM)
- 0.92
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.91 | $-1.89 | -0.0210 | -1.11% |
|
Sep 2025 (Q3)
|
$-3.04 | $-1.94 | -1.1020 | -56.86% |
|
Jun 2025 (Q2)
|
$-1.53 | $-2.41 | +0.8806 | +36.53% |
|
Mar 2025 (Q1)
|
$-2.11 | $-2.85 | +0.7426 | +26.03% |
Financial Statements
| Revenues | $2.19M |
| Benefits Costs and Expenses | $26.07M |
| Costs And Expenses | $26.07M |
| Operating Expenses | $90.17M |
| Research and Development | $69.45M |
| Other Operating Expenses | $20.72M |
| Operating Income/Loss | -$87.99M |
| Income/Loss From Continuing Operations After Tax | -$24.19M |
| Income/Loss From Continuing Operations Before Tax | -$23.88M |
| Income Tax Expense/Benefit | $314.00K |
| Income Tax Expense/Benefit, Current | $314.00K |
| Interest Income/Expense After Provision For Losses | $2.20M |
| Interest Income/Expense Operating, Net | $2.20M |
| Net Income/Loss | -$24.19M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$24.19M |
| Net Income/Loss Available To Common Stockholders, Basic | -$24.19M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$2.45 |
| Diluted Earnings Per Share | -$2.45 |
| Basic Average Shares | 9,884,955 |
| Diluted Average Shares | 9,884,955 |
| Assets | $88.53M |
| Current Assets | $82.86M |
| Cash | $77.80M |
| Other Current Assets | $5.06M |
| Noncurrent Assets | $5.67M |
| Fixed Assets | $1.87M |
| Other Non-current Assets | $3.80M |
| Liabilities | $34.99M |
| Current Liabilities | $21.23M |
| Accounts Payable | $3.98M |
| Wages | $7.46M |
| Other Current Liabilities | $9.79M |
| Noncurrent Liabilities | $13.76M |
| Equity | $53.55M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $53.55M |
| Liabilities And Equity | $88.53M |
| Net Cash Flow From Operating Activities | -$82.50M |
| Net Cash Flow From Operating Activities, Continuing | -$82.50M |
| Net Cash Flow From Investing Activities | -$37.83M |
| Net Cash Flow From Investing Activities, Continuing | -$37.83M |
| Net Cash Flow From Financing Activities | $101.64M |
| Net Cash Flow From Financing Activities, Continuing | $101.64M |
| Net Cash Flow | -$18.69M |
| Net Cash Flow, Continuing | -$18.69M |
| Comprehensive Income/Loss | -$24.18M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$24.18M |
| Other Comprehensive Income/Loss | -$24.18M |
| Other Comprehensive Income/Loss Attributable To Parent | $17.00K |